Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study

Citation
Kohsaka S, Lam CSP, Kim DJ, et al. Lancet Diabetes Endocrinol 2020;8:606–15